YTHDF2-mediated m6A modification of ONECUT2 promotes stemness and oxaliplatin resistance in gastric cancer through transcriptionally activating TFPI

IF 15.8 1区医学 Q1 PHARMACOLOGY & PHARMACY

Drug Resistance Updates Pub Date : 2025-01-02 DOI:10.1016/j.drup.2024.101200

Xingdi Fan, Fangyi Han, Haocheng Wang, Zhilin Shu, Bowen Qiu, Fanan Zeng, Hongzhen Chen, Ziying Wu, Yongwei Lin, Zhien Lan, Zhiwei Ye, Yao Ying, Tiansu Geng, Ziqian Xian, Xing Niu, Junming Wu, Ke Mo, Kehong Zheng, Yaping Ye, Chunhui Cui

引用次数: 0

Abstract

Chemoresistance results in poor outcomes of patients with gastric cancer (GC). This study aims to identify oxaliplatin resistance-related cell subpopulations in the tumor microenvironment (TME) and decipher the involved molecular mechanisms.

查看原文本刊更多论文

ythdf2介导的m6A修饰ONECUT2通过转录激活TFPI促进胃癌的干性和奥沙利铂耐药

化疗耐药导致胃癌（GC）患者预后不良。本研究旨在鉴定肿瘤微环境（TME）中与奥沙利铂耐药相关的细胞亚群，并破译相关的分子机制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Drug Resistance Updates 医学-药学

CiteScore

26.20

自引率

11.90%

发文量

审稿时长

29 days

期刊介绍： Drug Resistance Updates serves as a platform for publishing original research, commentary, and expert reviews on significant advancements in drug resistance related to infectious diseases and cancer. It encompasses diverse disciplines such as molecular biology, biochemistry, cell biology, pharmacology, microbiology, preclinical therapeutics, oncology, and clinical medicine. The journal addresses both basic research and clinical aspects of drug resistance, providing insights into novel drugs and strategies to overcome resistance. Original research articles are welcomed, and review articles are authored by leaders in the field by invitation. Articles are written by leaders in the field, in response to an invitation from the Editors, and are peer-reviewed prior to publication. Articles are clear, readable, and up-to-date, suitable for a multidisciplinary readership and include schematic diagrams and other illustrations conveying the major points of the article. The goal is to highlight recent areas of growth and put them in perspective. *Expert reviews in clinical and basic drug resistance research in oncology and infectious disease *Describes emerging technologies and therapies, particularly those that overcome drug resistance *Emphasises common themes in microbial and cancer research